文献类型：期刊文献

中文题名：中成药联合西医常规治疗冠心病合并高脂血症的网状Meta分析

英文题名：Network Meta-analysis of Chinese patent medicine combined with conventional western medicine in treatment of coronary heart disease with hyperlipidemia

作者：孔繁婷[1,2];任鹏[1,2];王薇[1,2];朱贝贝[1,2];刘凯[1,2]

第一作者：孔繁婷

机构：[1]甘肃中医药大学,甘肃兰州730000;[2]甘肃中医药大学循证医学中心,甘肃兰州730000

第一机构：甘肃中医药大学

年份：2024

卷号：55

期号：4

起止页码：1281

中文期刊名：中草药

外文期刊名：Chinese Traditional and Herbal Drugs

收录：CSTPCD;;Scopus;北大核心:【北大核心2023】；CSCD:【CSCD2023_2024】；

基金：甘肃省高等学校创新基金项目(2021B-172);甘肃省“双一流”科研重点项目(GSSYLXM-05)。

语种：中文

中文关键词：中成药;冠心病;高脂血症;网状Meta分析;复方丹参滴丸;脑心通胶囊;麝香保心丸;通心络胶囊;血脂康胶囊;银丹心脑通软胶囊;银杏叶片;脂必泰胶囊

外文关键词：Chinese patent medicine;coronary heart disease;hyperlipidemia;network Meta analysis;Compound Danshen Dropping Pills;Naoxintong Capsule;Shexiang Baoxin Pills;Tongxinluo Capsule;Xuezhikang Capsule;Yindan Xinnaotong Soft Capsule;Ginkgo Biloba Leaves Extract Tablets;Zhibitai Capsule

摘要：目的运用网状Meta分析不同中成药联合西医常规治疗冠心病合并高脂血症的有效性和安全性。方法计算机检索中国知网、维普、万方、中国生物医学文献数据库、PubMed、Cochrane Library、Embase、Web of Science,搜集建库至2022年11月28日所发表的中成药治疗冠心病合并高脂血症的随机对照试验(randomized controlled trials,RCTs),采用RevMan 5.3、Stata 16.0软件进行数据统计分析。结果最终纳入77项RCTs,共8775例患者及8种中成药。网状Meta分析结果显示:在降低血清总胆固醇(total cholesterol,TC)方面,累积排序曲线下面积(surface under the cumulative ranking curve,SUCRA)排名前3的干预措施为通心络胶囊联合西医常规、脑心通胶囊联合西医常规、银丹心脑通软胶囊联合西医常规;在降低低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)方面,SUCRA排名前3的干预措施是通心络胶囊联合西医常规、脑心通胶囊联合西医常规、复方丹参滴丸联合西医常规;在提高临床总有效率方面,SUCRA排名前3的干预措施是脂必泰胶囊联合西医常规、麝香保心丸联合西医常规、血脂康胶囊联合西医常规;在改善心绞痛疗效方面,SUCRA排名前3的干预措施是银丹心脑通软胶囊联合西医常规、通心络胶囊联合西医常规、复方丹参滴丸联合西医常规;在改善心电图疗效方面,SUCRA排名前3的干预措施是复方丹参滴丸联合西医常规、银杏叶片联合西医常规、通心络胶囊联合西医常规;在增加心输出量(cardiac output,CO)方面,SUCRA排名前3的干预措施是通心络胶囊联合西医常规、银杏叶片联合西医常规、复方丹参滴丸联合西医常规;在安全性方面,试验组发生不良反应事件少于对照组。结论不同中成药联合常规西医治疗冠心病合并高脂血症有效且各有优势,但由于纳入的研究少,研究质量一般,不同治疗方案间疗效排序差异大,以上排序结果还需今后开展高质量、大样本、随机双盲试验加以佐证。
Objective To analyse the effectiveness and safety of different Chinese patent medicines combined with conventional western medicine in the treatment of coronary heart disease complicated with hyperlipidemia by using network meta-analysis.Methods Randomized controlled trials(RCTs)of Chinese patent medicine in the treatment of coronary heart disease complicated with hyperlipidemia were collected by computer retrieval from CNKI,VIP,Wanfang and CBM,PubMed,Embase,Cochrane Library,Web of Science.The search time was from the establishment to November 28,2022.The data were statistical analyzed by RevMan 5.3 and Stata 16.0.Results A total of 77 RCTs were included,with 8775 patients and eight kinds of Chinese patent medicines involved.The results of network Meta-analysis showed that in terms of lowering serum total cholesterol(totalcholesterol,TC),the top three in surface under the cumulative ranking curve(SUCRA)were conventional treatment of western medicine combined with Tongxinluo Capsule(通心络胶囊),combined with Naoxintong Capsule(脑心通胶囊),combined with Yindan Xinnaotong Soft Capsule(银丹心脑通软胶囊).In terms of lowering low-density lipoprotein cholesterol(LDL-C),the top three in SUCRA were conventional treatment of western medicine combined with Tongxinluo Capsule,combined with Naoxintong Capsule,combined with Compound Danshen Dripping Pills(复方丹参滴丸).In terms of improving the total clinical efficacy,the top three in SUCRA were conventional treatment of western medicine combined with Zhibitai Capsule(脂必泰胶囊),combined with Shexiang Baoxin Pills(麝香保心丸),combined with Xuezhikang Capsule(血脂康胶囊).In terms of improving the efficacy of angina pectoris,the top three in SUCRA were conventional treatment of western medicine combined with Yindan Xinnaotong Soft Capsule,combined with Tongxinluo Capsule,combined with Compound Danshen Dripping Pills.In terms of improving the efficacy of electrocardiograph,the top three in SUCRA were conventional treatment of western medicine combined with Compound Danshen Dripping Pills,combined with Ginkgo Biloba Leaves Extract Tablets(银杏叶片),combined with Tongxinluo Capsule.In terms of increasing cardiac output,the top three in SUCRA were conventional treatment of western medicine combined with Tongxinluo Capsule,combined with Ginkgo Biloba Leaves Extract Tablets,combined with Compound Danshen Dripping Pills.In terms of safety,the incidence of adverse reactions in the treatment group was less than that in the control group.Conclusion Different Chinese patent medicines combined with conventional western medicine in the treatment of coronary heart disease with hyperlipidemia are effective and have their own advantages.However,due to the small number of included studies,the quality of the studies was general,and the efficacy ranking varied greatly among different treatment schemes,the above ranking results need to be confirmed by high-quality,large sample and randomized double-blind trials in the future.